Category: Hepatitis C

Combination Therapy of Sofosbuvir and Daclatasvir- Effective for Hepatitis C Related Cirrhosis

Sofosbuvir and daclatasvir combination therapy (SOF/DCV) is safe and effective for real-world treatment of patients with liver cirrhosis associated with hepatitis C virus (HCV) genotype 4, according to a study published in Alimentary Pharmacology & Therapeutics.

The randomized, multicenter, open-label study took place in 2016 at 4 separate clinical settings in Egypt. A total of 551 patients with hepatitis C virus genotype 4 and related liver cirrhosis were included in the study; 119 (21.6%) had been previously treated and 432 (78.4%) were naive to treatment.

Patients were treated according to the recommendations set by the European Association for the Study of the Liver in 2015, completing 12-week treatment regimens with SOF 400 mg and DCV 60 mg once daily, with the addition of daily weight-based dosages of ribavirin (RBV). When RBV was contraindicated, duration of treatment was extended to 24 weeks.


Efficacy of Simeprevir, Daclatasvir, Sofosbuvir for HCV Genotype 1

Six and eight-week regimens of simeprevir, daclatasvir, and sofosbuvir proved highly effective for treatment-naive patients with hepatitis C virus (HCV) genotype 1 (GT1) and early-stage liver fibrosis or compensated cirrhosis, according to a study published in the Journal of Viral Hepatitis.

ACCORDION ( Identifier: NCT02349048) was a phase 2, open-label, multicenter study conducted at 8 sites in the United States and Canada between January 21, 2015, and May 5, 2016. Participant eligibility was based on the following criteria: confirmed chronic HCV GT1 infection with early-stage liver fibrosis or compensated cirrhosis, a body mass index of 18 kg/m2 to 35 kg/m2, plasma HCV RNA >10 000 IU/mL at screening, naive to treatment for HCV, and eligible for treatment with pegylated interferon and ribavirin. Study participants with early-stage fibrosis were given simeprevir 150 mg, daclatasvir 60 mg, and sofosbuvir 400 mg once daily for 6 weeks, and participants with compensated cirrhosis were given the same regimen for 8 weeks.

The study aimed for a sample size of 60 participants in the 6-week group and 30 in the 8-week group, but only 68 patients met the stipulated FibroSURE™ and APRI [aspartate aminotransferase to platelet ratio index] score cut-offs in the study protocol. As a result, there were 59 patients included in the 6-week group and 9 patients in the 8-week group.


Studies Support Shortened, 8-Week HCV Treatment

Evidence supporting the FDA-approved option to shorten treatment of hepatitis C virus (HCV) genotypes 1 and 3 infection without cirrhosis with glecaprevir-pibrentasvir (Mavyret) from 12 weeks to 8 was drawn from two large multicenter trials involving over 1200 patients.

Analysis of data from the phase 3, open-label trials comparing 8 and 12-week regimens was recently consolidated in a report published by Stefan Zeuzem, MD, Professor of Medicine and Chief, Department of Medicine I, Goethe University Hospital, Frankfurt, Germany and colleagues.

“Although the current standard-of-care treatments for patients without cirrhosis who are infected with HCV genotype 1 or genotype 3 result in high rates of sustained virologic response (SVR), patients could benefit from shorter-duration treatment options that maintain high efficacy irrespective of HCV genotype,” Zeuzem and colleagues noted.

The ENDURANCE-1 trial evaluated the efficacy and safety of the fixed dose combination of glecaprevir-pibrentasvir (GLE-PIB) in HCV genotype 1-infected patients, including those with human immunodeficiency virus type 1 (HIV-1) co-infection. Patients were randomized in a 1:1 ratio to receive GLE-PIB for either 8 or 12 weeks.

The ENDURANCE-3 trial compared efficacy and safety of GLE-PIB to treatment with sofosbuvir (Sovaldi) dosed with daclatasvir (Daklinza) in treatment-naive patients with genotype 3 infection. Initially, patients were randomized in a 2:1 ratio to receive either GLE-PIB (3 tablets yielding 300mg glecaprevir and 120mg pibrentasvir) or the combination of 400mg of sofosbuvir with 60mg daclatasvir daily for 12 weeks. After the availability of preliminary data supporting the efficacy of an 8-week regimen, the protocol was amended to include a third group for 8 weeks of treatment with GLE-PIB.

“Until recently, there were no approved treatment regimens with a duration of less than 12 weeks for patients with HCV genotype 3 infection,” said Zeuzem and colleagues, “and 8-week treatment options for patients with genotype 1 infection were limited according to virus subtype, treatment history, fibrosis stage, or baseline viral load.”

Zeuzem and colleagues reported that the SVR at 12 weeks was 99.1% among genotype 1-infected patients receiving 8 weeks of GLE-PIB, compared with 99.7% treated for 12 weeks. In patients with genotype-3 infection treated for 12 weeks, 95% receiving GLE-PIB and 97% receiving sofosbuvir/daclatasvir attained SVR. Ninety-five percent of the patients with genotype 3 infection treated with 8 weeks of GLE-PIB also attained SVR measured at 12 weeks.


Newer drugs make hepatitis C-positive kidneys safe for transplant

People who received kidneys from donors infected with hepatitis C did not become ill with the virus, thanks to treatment with newer drugs that can cure the disease, a small study reports.

Ten patients not previously infected with hepatitis C took doses of powerful antiviral medications before and after receiving the transplants. None of the patients developed chronic infections, researchers report online March 6 in the Annals of Internal Medicine. The finding could help make more kidneys available for transplants.

“If this increases access to transplantation, then this is a great benefit,” says Jay Fishman, a transplant infectious disease specialist at Massachusetts General Hospital in Boston.

As of January 2016, more than 100,000 people in the United States were awaiting transplants, according to the National Kidney Foundation. In many areas, patients can linger on waiting lists for more than five years. In 2014, there were about 17,000 kidney transplants in the country, and nearly 4,800 people died while waiting.

Traditionally, organs from donors with hepatitis C were offered to recipients already infected with the disease, because the virus could be transmitted during a transplant. And one of the main drugs previously used to treat the infectious liver disease was not very effective and had many side effects, including the possibility of transplant rejection. But in the last several years, more effective drugs, called direct-acting antivirals, have been approved for use. These drugs cure hepatitis C in more than 95 percent of patients.

At the same time, more hepatitis C-positive organs have become available. The increase is likely due to rising numbers of overdose deaths from opioids (SN: 6/10/17, p. 22), says Christine Durand, a transplant infectious disease specialist at Johns Hopkins School of Medicine.


Myhep LVIR is the combination Ledipasvir/Sofosbuvir

Mylan Pharma, has launched Ledipasvir 90 mg/Sofosbuvir 400 mg tablets under the brand name MyHep LVIR™ in India.

Dosage Information-
• The product is a single-tablet regimen and requires a treatment of just 12 weeks.
• Prescribed for 12 weeks for genotypes 1, 2 and 3 while 24 weeks for genotype 4.

For Purchase Myhep LVIR at best price than you can contact on below details,

You can go throught our wesite-

Velpanat (Velpatasvir and Sofosbuvir)

Velpanat is the combination medicine of Velpatasvir and Sofosbuvir which is manufactured by NATCO Pharma and available as 400 mg Sofosbuvir and 100 mg Velpatasvir as 28 Tablets in one bottle and it is used in the treatment of Chronic Hepatitis C.

We can help patients in accessing/importing VELPANAT at best discount, unapproved in their home country against a Valid prescription.

Please contact +91 8130290915 for VELPANAT price in India and send mail at

Hepatitis C Treatment

What is Hepatitis C Virus?

Hepatitis C is an Infectious disease caused by Hepatits C Virus that infects the liver. During the initial infection people often have mild or no indications.Over many years however, it often leads to liver illness and cirrhosis. in some cases people with cirrhosis will develop complications such as liver faliure, liver cancer.

Hepatitis C virus is spread through contact with the blood of an infected person. Hepatitis C can be either “acute” or “chronic.”

Acute HCV infection is a short-term illness that occurs 15 % of cases. Symptoms includes a decreased appetite,weight loss, fatigue, nausea, muscle pains and joint pains, acute liver failure result.

Chronic Hepatitis C virus infection is a long-term illness that occurs 80% of cases. Hepatitis C virus infection can last a lifetime and cause serious liver problems, including cirrhosis or liver cancer.

How to get access Hepatitis C medications?

The Indian Pharma will help you to provide HCV medications by connecting Patients, Pharmacies and Retail stores through approved supplier, exporter and distributor of Generic medications.

In India HCV medications is marketed by diffrent Trade Name/Brand Name

The Innovator brand is available by International Trade Name/ Brand Name.

Patients, Pharmacies and Retail stores of generic medications can contact us by filling up the query form for further details relating to Generic medications, Innovator Brands and Biosimilar medical products.

Delivery of Hepatitis C medications

The Indian Pharma ( helps patient in connecting to the genuine pharmaceutical supplier to help access genuine medicine/ pharmaceutical drug (prescription drug, prescription medication or prescription medicine) that legally requires a medical prescription to be dispensed in following countries as per the customer’s prescribed medication and applicable regulatory approval.